2 Other possible side effects include acute cholelithiasis, hypersensitivity reactions, acute kidney injury secondary to undesirable GI side effects, and thrombocytopenia
Serious Risks Hypoglycemia (low blood sugar): Rare on its own, but a potential risk when combined with insulin or insulin-stimulating drugs
Boston, MA Frequently asked questions In the SURMOUNT-1 trial published in The New England Journal of Medicine (Jastreboff et al., 2022), participants on weekly tirzepatide 15 mg lost an average of 20.9% of body weight at 72 weeks versus 3.1% on placebo
While early studies and patient reports are encouraging, comprehensive clinical data for BPC-157 in humans are still emerging
In-person visits for labs and your initial exam take place at the Sanibel office, about 25 minutes from Fort Myers